The present invention relates to ligands of the peripheral cannabinoid receptor CB.sub.2, especially (+)-.alpha.-pinene derivatives, and to pharmaceutical compositions comprising these compounds, and to the use of such compounds for treatment and prevention of the onset of genetic neurodegenerative disorders, in particular Huntington's disease.